Cardiff University student ME/CFS Project – can you help?

Posted on 03/12/2021 by wames

Cardiff University Project – GP info leaflet

 

My name is Imogen Young and I’m a 3rd year medical student at Cardiff University.

I’m taking part in a 6-week project to produce an informative leaflet for GPs about diagnosis and management of Myalgic Encephalitis/Chronic Fatigue Syndrome (ME/CFS).

I’m looking to speak to a handful of volunteers with ME/CFS in a telephone interview about your experiences in primary care. I also want to gain an insight into the experience of living with ME/CFS.

All volunteers should be over 18 years old and be well enough to speak for 15-30 minutes without deterioration to your health.

Please contact me on Youngi1@Cardiff.ac.uk if you wish to be involved.

Posted in News | Tagged , , | Comments Off on Cardiff University student ME/CFS Project – can you help?

Perceptions of European ME/CFS experts concerning knowledge & understanding of ME/CFS among primary care physicians in Europe

Posted on 03/10/2021 by wames

Perceptions of European ME/CFS experts concerning knowledge and understanding of ME/CFS among primary care physicians in Europe: a report from the European ME/CFS Research Network (EUROMENE), by John Cullinan, Derek F H Pheby, Diana Araja, Uldis Berkis, Elenka Brenna, Jean-Dominique de Korwin, Lara Gitto, Dyfrig A Hughes, Rachael M Hunter, Dominic Trepel, Xia Wang-Steverding in Medicina (Kaunas) Vol 57, #3, p 208, Feb 26, 2021 [doi.org/10.3390/medicina57030208]

 

Research abstract:

Background and Objectives

We have conducted a survey of academic and clinical experts who are participants in the European ME/CFS Research Network (EUROMENE) to elicit perceptions of general practitioner (GP) knowledge and understanding of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and suggestions as to how this could be improved.

 

Materials and Methods

A questionnaire was sent to all national representatives and members of the EUROMENE Core Group and Management Committee. Survey responses were collated and then summarized based on the numbers and percentages of respondents selecting each response option, while weighted average responses were calculated for questions with numerical value response options. Free text responses were analysed using thematic analysis.

Results

Overall there were 23 responses to the survey from participants across 19 different European countries, with a 95% country-level response rate.

Serious concerns were expressed about GPs’ knowledge and understanding of ME/CFS, and, it was felt, about 60% of patients with ME/CFS went undiagnosed as a result. The vast majority of GPs were perceived to lack confidence in either diagnosing or managing the condition. Disbelief, and misleading illness attributions, were perceived to be widespread, and the unavailability of specialist centres to which GPs could refer patients and seek advice and support was frequently commented upon.

There was widespread support for more training on ME/CFS at both undergraduate and postgraduate levels.

Conclusion

The results of this survey are consistent with the existing scientific literature. ME/CFS experts report that lack of knowledge and understanding of ME/CFS among GPs is a major cause of missed and delayed diagnoses, which renders problematic attempts to determine the incidence and prevalence of the disease, and to measure its economic impact. It also contributes to the burden of disease through mismanagement in its early stages.

Posted in News | Tagged , , , , , , , , , , , , | Comments Off on Perceptions of European ME/CFS experts concerning knowledge & understanding of ME/CFS among primary care physicians in Europe

Managing COVID-19 post viral fatigue syndrome

Posted on 03/07/2021 by wames

Managing COVID-19 post viral fatigue syndrome, by Charles W Lapp and Joseph F John  in Fatigue: Biomedicine, Health & Behavior, Feb 22, 2021

 

Article abstract:

In online surveys, over 50% of persons who contract COVD-19 experience symptoms lasting longer than 90 days [Pelanti S, Grassi E, Markris N, et al. J Psych Res. 2020. doi:10.1016/j.jpsychires.2020.08.008]

Despite an estimated 3 million Americans being affected by COVID post-viral fatigue, there has been little discussion about the care of these patients, most of whom report feeling unsupported or dismissed by their providers [Amitay O, Komaroff AL. The Guardian, 20 Aug 2020].

This article points out the similarity between this post-viral fatigue syndrome and Chronic Fatigue Syndrome (ME/CFS) or Systemic Exertion Intolerance Disease (SEID), and offers evidence-based suggestions for management.

Recommendations for management

One year has elapsed with the COVID-19 pandemic, and it appears that this novel virus is capable of causing a syndrome similar to ME/CFS, as many other infections have done in the past. There is currently no Standard of Care for the management of such Long Haulers, so our recommendations are based on past experiences with SARS, expert opinion, our experience with ME/CFS, as well as expanding knowledge of COVID-19 illness. Here, we offer a sequence for diagnosis and treatment based primarily on our experience treating ME/CFS.

First, a rigorous history and physical examination should commence care. Second, routine testing should be performed to establish a baseline and to rule out sequelae of the disease that might produce chronic fatigue (see Table 2). Third, patients should be encouraged to rest frequently and aggressively and to set limits on daily activities so as to avoid exacerbations of their symptoms and post-exertional malaise. Overexertion leads to a prolonged exacerbation of symptoms (known as ‘post-exertional malaise’ or PEM) in persons with ME/CFS, and empirically we know that repeated PEM perpetuates or worsens the illness. Therefore, it is imperative that patients be advised to limit activity and balance activity with adequate rest in order to avoid PEM. Finally, clinicians can address the major issues of sleep disruption, pain, orthostatic symptoms, headache, and other co-morbidities so common in ME/CFS. These symptoms can be managed in the usual manner or referral to specialists.

Sleep disruption frequently responds to simple measures such as melatonin, over-the-counter antihistamines (such as diphenhydramine or doxylamine), or low doses of amitriptyline, nortriptyline, or trazodone. Primary sleep disorders are common in ME/CFS, so highly consider specialist referral and polysomnography if sleep remains problematic.

Pain is very common in ME/CFS but is frequently managed with physical therapies (hot or cold packs, Epsom soaks, massage, topical creams or liniments). In the past few years, low dose naltrexone (0.1–5 mg daily) has proved to be useful for myalgic pain. For more severe pain non-narcotic pain medications such as pregabalin, duloxetine or milnacipran are recommended. Opiates – if considered appropriate – might best be prescribed by a pain specialist.

Orthostatic symptoms such as lightheadedness, dizziness, upright intolerance, orthostatic hypotension or tachycardia, and even neurally mediated hypotension are common in ME/CFS. Management begins with volume expansion (drinking at least 64 ounces of water or non-caffeinated beverage daily and ingesting extra salt – if not hypertensive). Tachycardia may require a beta-blocker for symptomatic relief. If orthostasis is not improved by volume expansion (including parenteral fluids) consider consultation by cardiology.

Treating fatigue requires novel approaches as fatigue may respond to agents that clinicians may not regularly employ in their routine practices. This constellation may involve caffeinated drinks, low dose naltrexone, the use of stimulants including modafinil and methylphenidate, and other agents including antivirals. Other modalities including a wide variety of non-prescription supplements may help optimize the patient’s health. The following supplements are recommended based on available evidence:

  • Vitamin C may shorten or lessen the symptoms of the common cold (frequently caused by coronaviruses), and benefit the immune system. Studies are underway looking at the potential of Vitamin C in more severe cases of COVID-19. A dose of 500 mg per day is generally safe, with a maximum of 2000 mg daily.

  • Vitamin D3: Research has shown that countries whose population had lower levels of 25-OH Vitamin D had a higher incidence of COVID, and individuals with higher levels of 25-OH Vitamin D at illness onset have a milder course and lower rate of ICU admissions. Consider at least 1000–2000 iu daily to start. Because Vitamin D is fat soluble, individuals with a high body mass will likely require more.

  • Echinacea increases NK Cell Activity thereby supporting, if needed, the body’s antiviral system. It has been used to prevent upper respiratory tract infections. The usual dose is 300 mg daily, and drug holidays are recommended to avoid stimulating autoantibodies. Echinacea is contraindicated in RA, lupus erythematosus, multiple sclerosis, and other conditions associated with autoantibodies.

  • B12 and folate. These serum levels tend to be low in persons with ME/CFS, suggesting that supplementation might be beneficial. Methyl-cobalamin is taken as 1000 mcg daily along with 400–1000 mcg daily of methyl-folate.

  • CoQ10 also tends to be low in persons with ME/CFS. This is the most ubiquitous cofactor in the human body and supplementation with 100–200 mg daily might benefit metabolism.

  • Turmeric (curcumin) is a spice used in curry and mustard. However, it possesses potent antioxidant activity and reduces inflammation. It is particularly useful for mild muscle and joint aching, but is contraindicated in pregnancy due to its ability to cause uterine contractions. The usual dose is 500 mg twice daily.

If for no other reason, supplementation may enhance one’s innate and adaptive immune response, suppress inflammation, and reduce oxidative stress. The literature suggests the use of Vitamins A, D, C, B12, B6 and folate; micronutrients zinc, iron, selenium, copper; and omega-3 fatty acids as essential. In COVID-19, Vitamin D, selenium, and iron seem to be most important.

Although their effect on COVID-19 is controversial, current guidelines recommend continuation of therapy with ACE inhibitors (ACEI) or angiotension receptor blockers (ARBs).

See the full article for:

Overview & testing of COVD-19

Post-viral & post-COVID fatigue

Post-Viral Fatigue Syndrome (PVFS) versus Chronic Fatigue Syndrome (ME/CFS)

Table 1. Criteria for the Clinical Diagnosis of ME/CFS

Table 2. Clinical and Laboratory Testing of COVID-19 Long Haulers

Online resources for long haulers and ME/CFS

Posted in News | Tagged , , , , , , | Comments Off on Managing COVID-19 post viral fatigue syndrome

Recursive ensemble feature selection provides a robust mRNA expression signature for ME/CFS

Posted on 03/04/2021 by wames

Recursive ensemble feature selection provides a robust mRNA expression signature for myalgic encephalomyelitis/chronic fatigue syndrome, by Paula I Metselaar, Lucero Mendoza-Maldonado, Andrew Yung Fong Li Yim, Ilias Abarkan, Peter Henneman, Anje A Te Velde, Alexander Schönhuth, Jos A Bosch, Aletta D Kraneveld, Alejandro Lopez-Rincon in Sci Rep. 2021 Feb 25;11(1):4541 [doi: 10.1038/s41598-021-83660-9]

 

Research abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic disorder characterized by disabling fatigue. Several studies have sought to identify diagnostic biomarkers, with varying results.

Representation of a DNA molecule that is methylated. The two white spheres represent methyl groups. They are bound to two cytosine nucleotide molecules that make up the DNA sequence.

Here, we innovate this process by combining both mRNA expression and DNA methylation data. We performed recursive ensemble feature selection (REFS) on publicly available mRNA expression data in peripheral blood mononuclear cells (PBMCs) of 93 ME/CFS patients and 25 healthy controls, and found a signature of 23 genes capable of distinguishing cases and controls. REFS highly outperformed other methods, with an AUC of 0.92.

We validated the results on a different platform (AUC of 0.95) and in DNA methylation data obtained from four public studies on ME/CFS (99 patients and 50 controls), identifying 48 gene-associated CpGs that predicted disease status as well (AUC of 0.97). Finally, ten of the 23 genes could be interpreted in the context of the derailed immune system of ME/CFS.

Posted in News | Tagged , , , , , , , , , , , , , , , , | Comments Off on Recursive ensemble feature selection provides a robust mRNA expression signature for ME/CFS

A systematic review of nutraceutical interventions for mitochondrial dysfunctions in ME/CFS

Posted on 03/03/2021 by wames

A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome, by  in Journal of Translational Medicine vol 19, no.: 81 (2021)

 

Review abstract:

Background
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating illness, characterised by persistent fatigue that is unrelieved by rest, in combination with a range of other disabling symptoms. There is no diagnostic test nor targeted treatment available for this illness. The pathomechanism also remains unclear. Mitochondrial dysfunctions have been considered a possible underlying pathology based on reported differences including structural and functional changes in ME/CFS patients compared to healthy controls. Due to the potential role that mitochondria may play in ME/CFS, mitochondrial-targeting nutraceutical interventions have been used to potentially assist in improving patient outcomes such as fatigue. The aim of this systematic review is to appraise literature assessing these nutraceuticals as a possible intervention for treating ME/CFS.

Methods
A systematic search of Pubmed, Embase, Medline (EBSCO host) and Web of Science (via Clarivate Analytics) for journal articles published between January 1995 and 10th November 2020 was conducted. Articles assessing nutraceutical interventions and ME/CFS patient outcomes were retrieved. Using specific inclusion and exclusion criteria, the list of articles was further refined. Quality was measured using the Rosendal scale.

Results
Nine intervention studies were included in this review. The studies investigated patient symptom severity changes such as altered fatigue levels in response to mitochondrial-targeting nutraceuticals. Improvements in fatigue levels were observed in six of the nine studies. Secondary outcomes assessed include biochemical, psychological, and quality of life parameters.

Conclusion
There is insufficient evidence on the effectiveness of mitochondria- targeting nutraceuticals in ME/CFS patients. Future well-designed studies are required to elucidate both the involvement of mitochondria in the pathomechanism of ME/CFS and the effect of mitochondrial-modifying agents on illness severity.

Posted in News | Tagged , , , , , , , | Comments Off on A systematic review of nutraceutical interventions for mitochondrial dysfunctions in ME/CFS

WAMES AGM 27th March 2021

Posted on 03/03/2021 by wames

Annual General Meeting of WAMES

 

The annual business meeting of the Welsh Association of ME & CFS Support will be held virtually to appoint officers, review past events and plan future activities. As Covid-19 continues to impact life at many levels we need to continue to adapt.

Please contact jan@wames.org.uk if you have anything to report to WAMES, or topics you wish us to discuss, or more importantly, if you would like to get involved with the running of WAMES or volunteer in any way.  WAMES is entirely run by volunteers and there is always more work than workers!

Could you be an Admin volunteer?

The secretary would welcome some assistance with the administration.

Please let Jan know if you wish to attend and you will be given a link to join the meeting nearer the time.

When:  Saturday 27th March 2020 at  11.30am

Posted in News | Tagged | Comments Off on WAMES AGM 27th March 2021

Elin Williams: the mind/body split

Posted on 03/02/2021 by wames

Disability talk blog post: The mind/body split, by Elin Williams

 

As a chronically ill workaholic, I have a slight problem. My mind and my body don’t always cooperate.

One races through the to-do list,  whilst the other demands rest. One produces a new idea just as the other retaliates. One likes to think it’s invincible, whilst the other, well, the other has plenty of evidence in its arsenal to prove otherwise.

I give you The Mind/Body Split.

Ironically, I’m experiencing this conflict as we speak; interrupting what should deservedly be a restful afternoon with intermittent bouts of writing as my mind gravitates towards this idea and all it wants to say about it.

It’s a peculiar divide.

I’d like to think that I have this enduring loyalty to looking after my body, to listening to its cries when things get a little too much. But I have to hold my hands up and say that I’m not always committed to dedicating the care it needs and deserves.

It’s an almost constant battle; the split stretches into a chasm, leaving space for some peculiar emotions to swell. For years, the commitment between my mind and body to look out for each other has been puckered and bruised.

When I’m too weak to do anything, my mind feels guilty for not being productive. When I attempt a small task, my body quivers under the strain.

I’ve always placed unnecessary pressure on myself in terms of my work, my studies, my writing, and doing the best I can…

…Every day unfolds in different directions when it comes to The Mind/Body Split: Sometimes, a splash of common sense exists between them, making it easier to mould the shape of the day into something that will satisfy them both.

But some are harder than others. My ME/CFS symptoms fluctuate from one day to the next, sometimes gripping me from the moment I wake up, whilst, on others, they progress as the hours stretch on. Take the other day, for example: It was early afternoon when a thicker veil of weakness started to cascade over me, alerting me to the fact that it was time for a break, time to stop. But did I?

I did not.

Here is where I’d usually find myself typing carefully constructed explanations, but honestly? It was simply a matter of that newly accepted task being too tantalising to dismiss. It needed to be done, and I knew the worry of completing it would eat away at my energy whilst resting, just as an extra 20 minutes at my desk would.

So I stayed.

You’d think that I’d be quite the pro at navigating this whole ME/CFS experience, having lived with the symptoms in various forms for the best part of the last ten years, but consistent evidence proves that I am very much not. I barely touch intermediate.

It’s this hierarchy that gets me. The way in which both entities fight for superiority: The way I let the thought of productivity erode the precious concept of rest. Or the way in which the layering of symptoms makes it impossible to see a task or an activity through.

Because, my mind doesn’t always take the lead. Sometimes the thoughts are cast in the symptom of brain fog, or my arms are too heavy, too weak, to reach for the laptop.

I’ve become better at accepting these moments, better at submitting to resting when I need to.

But over-exertion is still a constant threat, and I know I need to make more of a conscious effort to diminish its presence…

Read the full article

Black tulip beauty: Elin Williams on life with vision impairment and CFS

Elin’s blog: My blurred world

Posted in News | Tagged | Comments Off on Elin Williams: the mind/body split

Mental health screening in adolescents with CFS/ME

Posted on 03/01/2021 by wames

Mental health screening in adolescents with CFS/ME, by Maria E Loades, Paul Stallard, David Kessler & Esther Crawley in European Child & Adolescent Psychiatry (2021) [doi.org/10.1007/s00787-021-01734-5]

 

Excerpts from Letter to the editor:

Psychiatric co-morbidity in adolescents is common, with the majority of those who have depression also having at least one anxiety disorder, and many meeting the diagnostic criteria for more than one anxiety disorder. In our recent paper published in this journal, we reported that approximately one in three adolescents with Chronic Fatigue Syndrome (CFS/ME) has either an anxiety disorder, or major depressive disorder, or both.

In clinical practice, screening questionnaires which ask about depression and anxiety symptoms, such as the Revised Children’s Anxiety and Depression Scale, RCADS, and the Hospital Anxiety and Depression Scale, HADS, are often used as part of the assessment process. However, in our paper, we reported our findings of variable discriminative validity of these questionnaires for detecting anxiety and depression separately. Whilst we found sufficiently accurate threshold scores for classifying those with anxiety disorders on both the 47-item and 25-item parent and child versions of the RCADS, we could not identify a sufficiently accurate threshold score for classifying those with depression. We also could not identify sufficiently accurate threshold scores on the HADS for either anxiety or depression.

Clinicians treating children with health disorders need a simple screening mechanism to identify those with co-morbid mental health problems that will require further assessment. Using one threshold score is therefore arguably more useful than calculating two separate scores (for depression and anxiety). Given the high co-morbidity between depression and anxiety in this population, we sought to identify the threshold score for mental health problems on two commonly used screening questionnaires, the RCADS-total and the HADS-total…

A total of 164 participants, mean age 15, mostly female (70%) completed the HADS and a subsample of 89 (54%) completed the RCADS. The subsample did not differ significantly on fatigue, physical functioning, HADS total, or age (data not shown)…

For identifying co-morbid mental health problems (anxiety and/or depression), we found that both the full 47-item version and the brief 25-item version of the RCADS were sufficiently accurate and could identify threshold scores deemed to be suitably sensitive and specific to be useful for screening in a clinical setting…

Participants were recruited from specialist services, so findings may not generalise to other settings, nor to those who were too severely affected to participate. The diagnostic interview was also assumed to be completely accurate, and whilst we made every attempt to ensure that it was robustly conducted, diagnostic judgements may mean that errors were made. Nonetheless, our findings suggest that a total cut-off score of ≥ 27 on the 25-item RCADS offers a simple way of identifying children with CFS/ME with co-morbid anxiety and depression.

Posted in News | Tagged , , , , , , , , | Comments Off on Mental health screening in adolescents with CFS/ME

Dysregulated provision of oxidisable substrates to the mitochondria in ME/CFS lymphoblasts

Posted on 02/24/2021 by wames

Dysregulated provision of oxidisable substrates to the mitochondria in ME/CFS lymphoblasts, by Daniel Missailidis, Oana Sanislav, Claire Y Allan, Paige K. Smith, Sarah J Annesley, and Paul R Fisher in Int. J. Mol. Sci. 2021, 22(4), 2046; 19 February 2021 [doi.org/10.3390/ijms22042046]  (This article belongs to the Special Issue Environmental Sensitivity Illnesses: Mechanisms and Molecular Signatures 2.0)

 

Research abstract:

Although understanding of the biomedical basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is growing, the underlying pathological mechanisms remain uncertain.

We recently reported a reduction in the proportion of basal oxygen consumption due to ATP synthesis by Complex V in ME/CFS patient-derived lymphoblast cell lines, suggesting mitochondrial respiratory inefficiency. This was accompanied by elevated respiratory capacity, elevated mammalian target of rapamycin complex 1 (mTORC1) signaling activity and elevated expression of enzymes involved in the TCA cycle, fatty acid β-oxidation and mitochondrial transport.  These and other observations led us to hypothesise the dysregulation of pathways providing the mitochondria with oxidisable substrates.

In our current study, we aimed to revisit this hypothesis by applying a combination of whole-cell transcriptomics, proteomics and energy stress signaling activity measures using subsets of up to 34 ME/CFS and 31 healthy control lymphoblast cell lines from our growing library.

While levels of glycolytic enzymes were unchanged in accordance with our previous observations of unaltered glycolytic rates, the whole-cell proteomes of ME/CFS lymphoblasts contained elevated levels of enzymes involved in the TCA cycle (p = 1.03 × 10−4), the pentose phosphate pathway (p = 0.034, G6PD p = 5.5 × 10−4), mitochondrial fatty acid β-oxidation (p = 9.2 × 10−3), and degradation of amino acids including glutamine/glutamate (GLS p = 0.034, GLUD1 p = 0.048, GOT2 p = 0.026), branched-chain amino acids (BCKDHA p = 0.028, BCKDHB p = 0.031) and essential amino acids (FAH p = 0.036, GCDH p = 0.006). The activity of the major cellular energy stress sensor, AMPK, was elevated but the increase did not reach statistical significance.

The results suggest that ME/CFS metabolism is dysregulated such that alternatives to glycolysis are more heavily utilised than in controls to provide the mitochondria with oxidisable substrates.

Posted in News | Tagged , , , , , , , , , , , | Comments Off on Dysregulated provision of oxidisable substrates to the mitochondria in ME/CFS lymphoblasts

Sex-based differences in plasma autoantibodies to CNS proteins in Gulf War veterans versus healthy & symptomatic controls

Posted on 02/22/2021 by wames

Sex-based differences in plasma autoantibodies to Central Nervous System proteins in Gulf War veterans versus healthy and symptomatic controls, by Mohamed B Abou-Donia, Maxine H Krengel, Elizabeth S Lapadula, Clara G Zundel, Jessica LeClair, Joseph Massaro, Emily Quinn, Lisa A Conboy, Efi Kokkotou, Daniel D Nguyen, Maria Abreu, Nancy G Klimas, Kimberly Sullivan in Brain Sci. 2021 Jan 23;11(2):148 [doi: 10.3390/brainsci11020148] (This article belongs to the Special Issue Advancing the Role of Neuroimmunity and Genetic Susceptibility in Gulf War Illness)

 

Research abstract

Veterans from the 1991 Gulf War (GW) have suffered from Gulf War illness (GWI) for nearly 30 years. This illness encompasses multiple body systems, including the central nervous system (CNS). Diagnosis and treatment of GWI is difficult because there has not been an objective diagnostic biomarker. Recently, we reported on a newly developed blood biomarker that discriminates GWI from GW healthy controls, and symptomatic controls with irritable bowel syndrome (IBS) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

The present study was designed to compare levels of these biomarkers between men and women with GWI, as well as sex-specific effects in comparison to healthy GW veterans and symptomatic controls (IBS, ME/CFS). The results showed that men and women with GWI differ in 2 of 10 plasma autoantibodies, with men showing significantly elevated levels. Men and women with GWI showed significantly different levels of autoantibodies in 8 of 10 biomarkers to neuronal and glial proteins in plasma relative to controls.

In summary, the present study addressed the utility of the use of plasma autoantibodies for CNS proteins to distinguish among both men and women veterans with GWI and other healthy and symptomatic control groups.

Excerpt

Our next analyses compared male veterans with GWI to all male controls from our prior study (healthy GW veterans, non-veterans with IBS or ME/CFS) [19]. We then performed the same analyses comparing women veterans with GWI to the combined all women control group (non-veterans with IBS and ME/CFS). The results showed that men with GWI had significantly higher levels of autoantibodies for 9 out of the 10 autoantibodies when compared with male healthy GW veterans or with the combined male control group. Women with GWI showed significantly higher values for 2 out of the 10 autoantibodies when compared with women healthy GW veterans and with 8 out of 10 autoantibodies when compared with their respective combined women control group (nonveterans with IBS and ME/CFS).

These results suggest that women with GWI appear to be showing more neuronal cytoskeletal and neuroinflammatory changes when compared to healthy GW controls or women with IBS or ME/CFS

This suggests that male GWI veterans may be showing more chronic glial activation, neuronal damage, and neuroinflammation than their male control healthy and symptomatic counterparts with IBS and ME/CFS because S100B is a marker of current BBB disruption and GFAP is a marker of current neuroinflammation [39,40]. This is because GFAP is secreted by activated astrocytes, which leads to neuroinflammation [41,42,43].

A major strength of our study is that it represents both healthy and symptomatic GW veteran groups as well as symptomatic non-veteran controls with ME/CFS or IBS. This suggests that both men and women veterans with GWI differ not only from their healthy GW veteran controls but also have more CNS differences than other groups of men and women with chronic multi-symptom illnesses. In addition, the CNS autoantibody analyses were performed with the laboratory staff blinded to the case status of all participants.

Posted in News | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Sex-based differences in plasma autoantibodies to CNS proteins in Gulf War veterans versus healthy & symptomatic controls